Cost-effectiveness analysis of lapatinib plus capecitabine versus capecitabine alone in the second line treatment for breast cancer treatment

被引：0
|
作者：
Ejzykowicz, F. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70201-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A60 / A61
页数：2
相关论文
共 50 条
  • [41] Capecitabine monotherapy in metastatic colorectal cancer - Effectiveness as first, second and third line treatment
    Schaberl-Moser, Renate
    Bauernhofer, Thomas
    Halm, Michael
    Pirchmoser, Renate
    Samonigg, Hellmut
    ANNALS OF ONCOLOGY, 2004, 15 : 95 - 95
  • [42] A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
    David Cameron
    Michelle Casey
    Michael Press
    Deborah Lindquist
    Tadeusz Pienkowski
    C. Gilles Romieu
    Stephen Chan
    Agnieszka Jagiello-Gruszfeld
    Bella Kaufman
    John Crown
    Arlene Chan
    Mario Campone
    Patrice Viens
    Neville Davidson
    Vera Gorbounova
    Johannes Isaac Raats
    Dimosthenis Skarlos
    Beth Newstat
    Debasish Roychowdhury
    Paolo Paoletti
    Cristina Oliva
    Stephen Rubin
    Steven Stein
    Charles E. Geyer
    Breast Cancer Research and Treatment, 2008, 112 : 533 - 543
  • [43] A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
    Cameron, David
    Casey, Michelle
    Press, Michael
    Lindquist, Deborah
    Pienkowski, Tadeusz
    Romieu, C. Gilles
    Chan, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Kaufman, Bella
    Crown, John
    Chan, Arlene
    Campone, Mario
    Viens, Patrice
    Davidson, Neville
    Gorbounova, Vera
    Raats, Johannes Isaac
    Skarlos, Dimosthenis
    Newstat, Beth
    Roychowdhury, Debasish
    Paoletti, Paolo
    Oliva, Cristina
    Rubin, Stephen
    Stein, Steven
    Geyer, Charles E.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) : 533 - 543
  • [44] COST EFFECTIVENESS ANALYSIS OF LAPATINIB/CAPECITABINE (LC) VERSUS TRASTUZUMAB/CAPECITABINE (TC) IN PATIENTS WITH METASTATIC BREAST CANCER ERBB2+AFTER PROGRESSION TO THE FIRST SCHEME OF TRASTUZUMAB
    Anaya, P.
    Aldaco, F.
    VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
  • [45] Lapatinib treatment with Capecitabine in a patient with scattered breast cancer along with metastases in the brain
    Makarewicz, Adrianna
    Zurawski, Bogdan
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 : D15 - D16
  • [46] Lapatinib with Capecitabine in the treatment of a breast cancer patient with metastases in the central nervous system
    Czartoryska-Arlukowicz, Bogumila
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 : D10 - D10
  • [47] Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective
    Sofrygin, O.
    Delea, T. E.
    Tappenden, P.
    Karnon, J.
    Browning, D.
    Amonkar, M.
    Lykopoulos, K.
    Cameron, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 443 - 443
  • [49] Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
    Chen, Ruijia
    Zhang, Yalan
    Lin, Kongying
    Huang, Defu
    You, MaoJin
    Lai, Yanjin
    Wang, Jinye
    Hu, Yingying
    Li, Na
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] Predictive significance of the mucocutaneous toxicities, but not dose intensity of capecitabine for the treatment of lapatinib plus capecitabine in patients with HER2 positive metastatic breast cancer
    Araki, K.
    Fukada, I.
    Takahashi, S.
    Ito, Y.
    CANCER RESEARCH, 2013, 73
12345